Could natural immune cells help fight leukemia drug resistance?

NCT ID NCT04965649

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study from France examined whether a specific type of immune cell (innate CD8+ T cells) is linked to how quickly resistance mutations develop in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Researchers analyzed blood samples from 30 adult patients already being treated with tyrosine kinase inhibitors (TKIs). The goal was to see if higher levels of these immune cells are associated with slower growth of drug-resistant cancer cells. This is an observational study, not a treatment trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could point toward new ways to predict or overcome drug resistance in certain leukemias.

What could go wrong

This is a small, completed observational study (30 participants) that only looks for associations, not a treatment. Results may not lead to direct patient benefits.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia with BCR-ABL1 chronic leukemia chronic myelogenous leukemia, BCR-ABL1 positive leukemia leukemia, acute lymphocytic, susceptibility to, 1 myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU de Nîmes

    Nîmes, Gard, 30029, France